Strategic Partnerships ProCrysta Biologix is actively pursuing strategic collaborative partnerships in purification, formulation, and drug delivery of biologics using its proprietary crystallization technology, presenting opportunities for collaboration, co-development, or contract research services with biotech firms, contract manufacturers, and academic laboratories.

Protein Therapeutics Focus The company's focus on novel protein therapeutics for infectious diseases and metabolic disorders, including PCB-101 for tuberculosis, highlights potential for licensing, joint development, or supply arrangements with TB programs, global health initiatives, and specialty pharma customers seeking targeted biologic enzymes.

Delivery Platform Crystallization-enabled formulation and multi-route delivery (oral, subcutaneous, topical, pulmonary) create cross-selling potential with contract development and manufacturing organizations (CDMOs), device developers, or pharma companies seeking differentiated biologic delivery solutions.

Early-stage Validation PCB-101 has demonstrated in vitro efficacy and progressing to in vivo studies, with NIH support, signaling potential for grant-backed collaborations, translational partnerships, and opportunities to engage health agencies or non-dilutive funding sources to de-risk development.

Lean Operations As a lean biotech with minimal current revenue, there is a clear sales opportunity to pursue fee-for-service CRO/CMO engagements, pilot collaboration projects, and early-stage licensing discussions to establish revenue streams while expanding the technology's reach.